📜 What This Document Is ℹ️

This is a Definitive Proxy Statement (a DEF 14A), which is a highly formal document filed with the SEC that tells shareholders exactly what decisions they will be voting on at the company's Annual Meeting. Think of it as a "playbook" for the annual meeting, outlining the board's performance, the proposed compensation for executives, and major operational changes.

👉 Why it matters: Because you (the shareholder) are being asked to vote on five major topics, including the company’s core financial structure (equity plan) and how executive leaders are paid. Reading this helps you vote with full knowledge.

🗓️ The Annual Meeting Details 🗓️

Veracyte is asking shareholders to vote at its Annual Meeting of Stockholders, which is scheduled for Wednesday, June 10, 2026, at 10:00 a.m., Pacific Daylight Time.

• Format: The meeting will be held virtually, accessible at www.virtualshareholdermeeting.com/VCYT2026.
• Voting Deadline: The official "Record Date" (the date used to determine who is entitled to vote) is the close of business on April 15, 2026.
• Key Action: The CEO, Marc Stapley, strongly emphasizes that shareholders vote as soon as possible, even if they plan to attend, to ensure their shares are represented.

🏢 What The Company Does 🧪

Veracyte, Inc. develops novel approaches to cancer care. While the filing doesn't detail specific product pipelines, its focus is clearly on life sciences and advanced diagnostics.

• Scale: As of December 31, 2025, the company had 755 employees.
• Workforce Distribution: The employees are segmented into:
  • Laboratory operations: 159
  • Research and development/clinical development: 124
  • Selling and marketing: 180
  • General and administrative: 292
• Culture & Mission: The company emphasizes its "Veracyte way," focusing on using science to help patients make life-changing decisions, and was named one of the Fortune Best Workplaces in BioPharma™ for 2025.

🏗️ Corporate Governance & Risk Oversight ⚙️

This section details the rules and safeguards Veracyte has in place to manage risk and guide the company’s operations. Governance is the system of rules and procedures that directs the company.

• Board Oversight: The Board of Directors actively oversees the company's strategy, budget, capital allocation, and major business initiatives. The oversight of risk is shared between the Board and executive management.
• Key Governance Highlights: The board operates with several best practices, including:
  • One-year terms for all directors.
  • 8 of 9 directors are independent.
  • A dedicated independent Chair of the Board.
  • Robust annual Board self-assessment processes.
• Committee Structure: The Board divides risk oversight among specialized committees to ensure comprehensive coverage:
  • Audit Committee: Oversees major financial risks, internal controls, cybersecurity, and data privacy.
  • Compensation Committee: Oversees pay and talent-related risks.
  • Nominating and Corporate Governance Committee: Focuses on board composition, corporate responsibility, and ESG matters.
  • Regulatory and Compliance Committee: Focuses on compliance with healthcare legal and regulatory requirements.
• Cybersecurity Risk: The Board and Audit Committee specifically oversee cybersecurity threats, requiring updates on developments, vulnerabilities, and any incidents that meet reporting thresholds.
• Ethics: The company has adopted a Code of Business Conduct and Ethics and maintains a confidential "whistleblower hotline" and online portal for reporting misconduct.

🛡️ Key Board & Committee Members 👥

The document lists the members and chairs of the critical Board committees for 2025:

• Audit Committee: Chair: Jens Holstein. Members: Karin Eastham, Evan Jones.
• Compensation Committee: Chair: Karin Eastham. Members: Jens Holstein, Brent Shafer.
• Nominating and Corporate Governance Committee: Chair: Robert S. Epstein. Members: Muna Bhanji, Evan Jones.
• Regulatory and Compliance Committee: Chair: Evan Jones. Members: Muna Bhanji, Eliav Barr, Tom Miller.

💰 Director Compensation Compensation 💸

The Compensation Committee provides a detailed breakdown of the total compensation paid to the non-employee directors for their service in 2025.

• Structure: Compensation includes a cash component (Fees Earned) and a significant equity component (Stock Awards).
• Total Compensation (2025): The total compensation ranges from $304,989 (Tom Miller) to $359,989 (Robert S. Epstein).
• Key Details: All amounts listed under "Stock Awards" represent the fair value of the equity awards, not necessarily the cash realized, and the awards are computed using accounting standards (ASC 718).

🧬 Proposed Amendment to the Equity Plan ✨

This is perhaps the most complex part of the filing. It asks shareholders to vote on approving an amendment to the existing Veracyte, Inc. 2023 Equity Incentive Plan. This essentially changes the rules for how the company grants stock and options to employees and directors.

• The Ask: The Board recommends increasing the share reserve under the 2023 Plan by 3,500,000 shares of common stock.
• Why it Matters (The Rationale): The Board argues that equity compensation is vital to attracting and retaining top talent in a competitive life sciences market. Without this increase, the company fears it would be limited and might have to rely more heavily and expensively on cash pay.
• Sustainability: The added shares are projected to be sufficient to cover anticipated grants for approximately one additional year.

📉 Equity Compensation Metrics & Dilution 📈

The Board provides granular metrics to justify the proposed share increase and show that the compensation spending is reasonable.

• Burn Rate: The company tracks its "burn rate" (how fast it grants shares). The three-year average burn rate for 2023–2025 was 2.68%.
  • Significance: The burn rate declined significantly from 3.34% in 2023 to 1.81% in 2025, suggesting improved efficiency or a natural leveling off of compensation costs.
• Equity Overhang: As of March 31, 2026, the total outstanding equity awards plus shares available under the 2023 Plan (the "overhang") represented approximately 19% of common stock outstanding.
  • Significance: The Board cites this metric to show the necessary scale of the requested shares (the 3.5 million increase, which is 4.4% of common stock outstanding) is a prudent amount relative to the existing compensation structure.
• Outstanding Shares: As of March 31, 2026, the total outstanding common stock was 79,791,856 shares.

📑 Other Voting Proposals 🗳️

Three other resolutions require shareholder votes at the meeting:

• Ratifying the Public Accounting Firm (E&Y): The Audit Committee proposes ratifying Ernst & Young LLP as the independent accounting firm for 2026.
  • Metrics: The audit fees for 2025 were $2,230,512, a decrease from $2,615,955 in 2024.
• "Say on Pay" Vote: This is a non-binding, advisory vote allowing stockholders to give feedback on the compensation of named executive officers.
  • Action: The Board and Compensation Committee recommend voting "FOR" this proposal.
• Approving the Plan Amendment: The Board recommends a vote "FOR" increasing the share reserve by 3.5 million shares.

🧑‍🤝‍🧑 Ownership Snapshot 💎

This section lists who owns the company.

• Major Institutional Holders (5%+):
  • BlackRock, Inc.: 11,930,018 shares (15.0%)
  • Artisan Partners Limited Partnership: 6,263,041 shares (7.8%)
  • FMR LLC: 5,688,209 shares (7.1%)
  • State Street Corporation: 4,199,674 shares (5.3%)
• Management Holdings: Marc Stapley, the CEO, holds 494,513 shares.

📞 Contact Information 📬

For more details, the following contact points are provided:

• Company Address: 6000 Shoreline Court, Suite 300 South San Francisco, CA 94080.
• General Counsel/Secretary Contact: The general counsel office at this address will review and forward any communications from stockholders to the appropriate Board director or committee.
• Website: The Proxy Statement and Annual Report are available at www.proxyvote.com.

---

🧠 The Analogy

Voting on a proxy statement is like inspecting the blueprints for a massive house renovation. The board members (the contractors) are presenting detailed plans on where the plumbing, wiring, and structure will go. Before they can move forward, the owners (the shareholders) must approve the revised plans—which include how much money is needed for the plumbing (compensation) and how many extra materials (shares) are required for future expansion. You need to understand the entire plan before giving your vote.

🧩 Final Takeaway

This proxy statement details Veracyte's corporate governance, requiring shareholder approval to significantly increase its equity share pool (by 3.5 million shares) to ensure it has the necessary financial tools to attract and retain top scientific and leadership talent.